Enemmän aikaa tavoitealueella2, , ympäri vuorokauden.

MiniMed™ 780G -‍järjestelmä säätelee automaattisesti  insuliinin annostelua ja korjaa korkeita glukoosiarvoja 5 minuutin välein, 24/7, ilman sormenpäämittauksia. 

0
%
aika tavoitealueella3
Järjestelmän käyttäjien
0
%
aika tavoitealueella

öisin on keskimäärin4, 

MiniMed™ 780G system

MiniMed™ 780G -järjestelmä

Nyt saatavilla yli 2-vuotiaille diabetesta sairastaville lapsille sekä raskaana oleville naisille.

MiniMed™ 780G system

Harkitsetko automaattista insuliinipumppu­järjestelmää?

Insuliinipumppua valittaessa on tärkeää varmistaa, että se vastaa omia tarpeita ja tuottaa parhaan tuloksen. Tärkeimpiä huomioon otettavia asioita ovat:

  • Aika tavoitealueella (TIR):
    Prosenttiosuus ajasta, jolloin glukoosiarvo on tavoitealueella. Korkeampi TIR vähentää komplikaatioita, kuten silmävaurioita (retinopatiaa), sydän- ja munuaissairauksia.5
  • Kuormituksen vähentäminen:
    Saavuta enemmän tekemällä vähemmän. Pumpun tulisi auttaa sinua pysymään tavoitealueella, vaikka hiilihydraattien laskeminen ei olisikaan tarkkaa.6

Lisätietoja
MiniMed™ 780G -‍järjestelmästä

Pyydä lisätietoja

Viitteet

  1. dQ&A US Patient Voice Q2 2025. p. 77. n=2152. Data on file. Abbott Diabetes Care, Inc.
  2. Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
  3. Arrieta A, et al. Diabetes Obes Metab. 2022; doi: 10.1111/dom.14714. Mean 80% TIR is reached using the recommended optimal settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
  4. McVean, et al. Diabetes Obes Metab. 2026;28(3):2456-2460
  5. De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
  6. Petrovski G, et al. Diabetes Care 2023;46(3):544–550
  7. Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
  8. Data on file, Abbott Diabetes Care, Inc.
  9. Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
  10. Alwan et al. (2023) doi: 10.1177/19322968231185348
  11. Kovatchev et al. (2022) doi:10.2337/dc22-1217
  12. Forlenza et al. (2024) doi:10.1089/dia.2023.0578
  13. Wheeler BJ, et al. Acta Diabetol. 2022;59(1):31-37.
  • * Adults, T1 and parents of children with T1 diabetes < 18 years were surveyed based on their experience with Guardian™ 4 sensor.
  • ** Compared to MDI + isCGM
  • ^ Katso tarkemmat tiedot SmartGuard™-ominaisuudesta käyttöoppaasta. Käyttäjän vuorovaikutusta vaaditaan.
  • ^^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • # Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. Overnight period: 12:00 AM- 6:00 AM [24:00 h – 06:00 h]. Number of users with ≥10 days of sensor glucose data
  • ∞ Reached using optimal settings. Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time
  • § Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. 1 with Medtronic Extended Infusion Set.
  • ◊ Based on RWE publications.
  • ~ The people with diabetes testimonials relates to the account of an individual's response to the treatment. The account is genuine, typical and documented. However, the individual's response does not provide any indication, guide, warranty or guarantee as to the response other people with diabetes may have to the treatment. The response other people with diabetes have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual people with diabetes.
  • ¥ Refer to Accu-Chek® Guide Link User's Manual
  • 1.dQ&A US Patient Voice Q2 2025. p. 77. n=2152. Data on file. Abbott Diabetes Care, Inc.
  • 2.Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
  • 3.Arrieta A, et al. Diabetes Obes Metab. 2022; doi: 10.1111/dom.14714. Mean 80% TIR is reached using the recommended optimal settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
  • 4.McVean, et al. Diabetes Obes Metab. 2026;28(3):2456-2460
  • 5.De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
  • 6.Petrovski G, et al. Diabetes Care 2023;46(3):544–550
  • 7.Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
  • 8.Data on file, Abbott Diabetes Care, Inc.
  • 9.Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
  • 10.Alwan et al. (2023) doi: 10.1177/19322968231185348
  • 11.Kovatchev et al. (2022) doi:10.2337/dc22-1217
  • 12.Forlenza et al. (2024) doi:10.1089/dia.2023.0578
  • 13.Wheeler BJ, et al. Acta Diabetol. 2022;59(1):31-37.
  • * Adults, T1 and parents of children with T1 diabetes < 18 years were surveyed based on their experience with Guardian™ 4 sensor.
  • ** Compared to MDI + isCGM
  • ^ Katso tarkemmat tiedot SmartGuard™-ominaisuudesta käyttöoppaasta. Käyttäjän vuorovaikutusta vaaditaan.
  • ^^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • # Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. Overnight period: 12:00 AM- 6:00 AM [24:00 h – 06:00 h]. Number of users with ≥10 days of sensor glucose data
  • ∞ Reached using optimal settings. Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time
  • § Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. 1 with Medtronic Extended Infusion Set.
  • ◊ Based on RWE publications.
  • ~ The people with diabetes testimonials relates to the account of an individual's response to the treatment. The account is genuine, typical and documented. However, the individual's response does not provide any indication, guide, warranty or guarantee as to the response other people with diabetes may have to the treatment. The response other people with diabetes have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual people with diabetes.
  • ¥ Refer to Accu-Chek® Guide Link User's Manual
  • ^ Katso tarkemmat tiedot SmartGuard™-ominaisuudesta käyttöoppaasta. Käyttäjän vuorovaikutusta vaaditaan.
  • ^^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • # Due to inherent real-world study limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. Overnight period: 12:00 AM- 6:00 AM [24:00 h – 06:00 h]. Number of users with ≥10 days of sensor glucose data
  • ∞ Reached using optimal settings. Optimal settings are glucose target at 100 mg/dL (5.5 mmol/L) and Active Insulin Time (AIT) at 2 hours and used >95% of the time

CE-DBA-2600170© 2026 Medtronic. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc.

The sensor shape and appearance, Abbott and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under licence. Sensor image © 2026 Abbott.

*Third–party brands are trademarks of their respective owners.

Onko sinulla vielä kysymyksiä?

Tästä pääset usein kysyttyihin kysymyksiin.

Siirry tukikeskukseen

Tästä voit ottaa yhteyttä meihin

Siirry yhteystietosivulle

Tuotetuen toimistoajat arkisin 9:00-23:00. Muina aikoina jätä viesti ja päivystäjämme soittaa sinulle takaisin. Puh. 0800 164 064

Katso tarkemmat käyttöohjeet, käyttöaiheet, vasta-aiheet, varotoimet, varoitukset ja mahdolliset haittatapahtumat laitteen käyttöoppaasta. Lisätietoja saat MiniMed paikalliselta edustajalta tai käyttöoppaasta. © 2026 MiniMed. Kaikki oikeudet pidätetään. MiniMed, MiniMed-logo ja Further, Together ovat MiniMed tavaramerkkejä. Kolmansien osapuolten tuotemerkit ovat omistajiensa tavaramerkkejä. Kaikki muut tuotemerkit ovat MiniMed-yrityksen tavaramerkkejä. MiniMed infuusiosettien laillinen valmistaja on Unomedical a/s. Aaholmvej 1–3, Osted. 4320 Lejre, Tanska.

MiniMed Finland Oy Kaikki oikeudet pidätetään Lentäjäntie 3, 01530 Vantaa, Suomi Finland.

Takaisin ylös